Early stroke treatment associated with better outcome: The NINDS rt-PA Stroke Study

Neurology

Volumn 55, Issue 11, 2000, Pages 1649-1655

  Marler, John R ^a   Tilley, B C ^a   Lu, M ^a   Brott, T G ^a   Lyden, P C ^a   Grotta, J C ^a   Broderick, J P ^a   Levine, S R ^a   Frankel, M P ^a   Horowitz, S H ^a   Haley Jr , E C ^a   Lewandowski, C A ^a   Kwiatkowski, T P ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ARTICLE; BRAIN HEMANGIOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034642165     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.11.1649     Document Type: Article

References (19)

1. Tissue plasminogen activator for acute ischemic stroke
2. Urgent therapy for stroke I. Pilot study of tissue plasminogen activator administered within 90 minutes
3. Urgent therapy for stroke II. Pilot study of tissue plasminogen activator administered within 90-180 minutes from onset
4. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke
5. Factors determining the therapeutic window for stroke
6. Functional evaluation: The Barthel Index
7. Interobserver agreement for the assessment of handicap in stroke patients
8. Observer variability in assessing impaired consciousness and coma
9. Clinical trial of nimodipine in acute ischemic stroke
10. Intracerebral hemorrhage after intravenous rt-PA therapy for ischemic stroke
11. Generalized efficacy of rt-PA for acute stroke: Subgroup analysis of the NINDS rt-PA stroke trial
12. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke rt-PA Trial
13. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke
14. Tissue plasminogen activator reduces neurological damage after cerebral embolism
15. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke
16. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care